# Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

> **NCT01099761** · PHASE2 · TERMINATED · sponsor: **Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA** · enrollment: 24 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **BIOLOGICAL:** ACE-031 0.5 mg/kg q4wk
- **BIOLOGICAL:** ACE-031 1.0 mg/kg q2wk
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01099761
- **Lead sponsor:** Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-04
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Based on preliminary safety data.
- **Last updated:** 2022-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01099761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01099761, "Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01099761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*